Cargando…
Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
Clinical trials have demonstrated that an increased number of effector cells, especially tumor-specific T cells, is positively linked with patients’ prognosis. Although the discovery of checkpoint inhibitors (CPIs) has led to encouraging progress in cancer immunotherapy, the lack of either T cells o...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society for Biochemistry and Molecular Biology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851446/ https://www.ncbi.nlm.nih.gov/pubmed/33407991 http://dx.doi.org/10.5483/BMBRep.2021.54.1.257 |